Memorial Sloan Kettering Cancer Center has patented antibodies that target CTLA-4 and PD-1 to enhance T cell activation in cancer patients. The method involves administering a therapeutic combination of specific antibodies. This innovation offers new possibilities for cancer treatment. GlobalData’s report on Memorial Sloan Kettering Cancer Center gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Memorial Sloan Kettering Cancer Center, was a key innovation area identified from patents. Memorial Sloan Kettering Cancer Center's grant share as of May 2024 was 30%. Grant share is based on the ratio of number of grants to total number of patents.
Monoclonal antibodies for cancer treatment by increasing t cell activation
A recently granted patent (Publication Number: US11993653B2) discloses a method for increasing T cell activation in cancer patients by administering a therapeutic combination of two isolated antibodies. The first antibody specifically binds to human CTLA-4, while the second antibody targets human PD-1. The antibodies are designed with specific amino acid sequences in their variable regions to enhance their efficacy in activating T cells. The method is particularly focused on treating subjects with various types of cancer, including metastatic or locally advanced solid tumors, cervical cancer, non-small cell lung cancer (NSCLC), and cutaneous squamous-cell carcinoma (cSCC), among others.
The patent outlines specific dosages and administration schedules for the antibodies, emphasizing the importance of the combination therapy in cases where standard treatments have failed or are not available. Additionally, the method is tailored for patients with specific characteristics, such as those with relapsed cancer after platinum-based chemotherapy, advanced or metastatic disease, or tumors expressing certain levels of PD-L1. By targeting key immune checkpoints, the therapeutic combination aims to enhance T cell activation and potentially improve outcomes for cancer patients who have limited treatment options. Overall, the patent provides a detailed framework for utilizing these antibodies in a precise and effective manner to boost the immune response against cancer cells and potentially improve patient outcomes.
To know more about GlobalData’s detailed insights on Memorial Sloan Kettering Cancer Center, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
